Amerikanische Gesellschaft für Hirudotherapie

Characterization of the digestive tract microbiota of Hirudo orientalis (medicinal leech) and antibiotic resistance profile

Research article published in Plastic and Reconstructive Surgery (2014)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikSicherheit & InfektionskontrolleWhitaker IS, Maltz M, Siddall ME, Graf J · Plastic and reconstructive surgery, 2014

Abstract

BACKGROUND: There are at least three distinct European leech species used medicinally: Hirudo medicinalis, H. orientalis, and H. verbana. Infection caused by leech microbiota is the most widely reported complication. Few studies have reported the culturable and unculturable bacteria and examined the antibiotic resistances in H. orientalis. METHODS: Following stratified random sampling from a major worldwide leech supplier, Hirudo orientalis leeches were identified by visual comparison and amplification and sequencing the cox1 locus. Combined culture and culture-independent approaches were used to characterize the microbiota of the midgut, and bacterial gyrB sequences from distinct colonies were used to identify the Aeromonas isolates. Nonculturable studies involved clone libraries of 16S rRNA genes, and Etests were used to investigate antibiotic sensitivities. RESULTS: Analysis of 16S rRNA gene clone libraries revealed the presence of several species in the intraluminal fluid of the crop, including a new finding of Morganella morganii, with Rikenella-like (35 percent) and Aeromonas veronii (38 percent) dominant members. The intestinum contained bacteria not previously isolated from the leech: Magnetospirillium species and Roseospira marina. Etests showed all A. veronii isolates were sensitive to ciprofloxacin, with either a complete or intermediate resistance to Augmentin. CONCLUSIONS: The authors show diverse microbiota in the leech digestive tract. The pathogenic potential of the additional gut symbionts isolated in this study is yet to be elucidated; however, M. morganii, which is a known human pathogen, is a new finding. In addition to adding to the knowledge base regarding antibiotic sensitivities, this article serves as an update to the reconstructive surgeon regarding leech therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAnimalsDrug Resistance, BacterialGastrointestinal TractHirudo medicinalisMicrobiota

Zusammenfassung

Combined culture and culture-independent methods identify Aeromonas veronii, Rikenella-like and Morganella morganii as members of the Hirudo orientalis digestive tract microbiota, with all A. veronii isolates sensitive to ciprofloxacin but partially resistant to Augmentin.

Warum dies für die Hirudotherapie relevant ist

This study characterized the digestive tract microbiota of Hirudo orientalis leeches from a major worldwide supplier using combined culture and culture-independent methods, identifying Rikenella-like bacteria and Aeromonas veronii as dominant members of the crop intraluminal fluid, along with new findings including the human pathogen Morganella morganii. Etests showed all A. veronii isolates were sensitive to ciprofloxacin but showed complete or intermediate resistance to Augmentin. This work is relevant to hirudotherapy because infection from leech microbiota is the most widely reported complication, and the authors state the article serves as an update to the reconstructive surgeon regarding leech therapy while adding to the knowledge base on antibiotic sensitivities. However, the pathogenic potential of the additional gut symbionts isolated remains to be elucidated.

Zitation

Characterization of the digestive tract microbiota of Hirudo orientalis (medicinal leech) and antibiotic resistance profile.

Whitaker IS, Maltz M, Siddall ME, Graf J · Plastic and reconstructive surgery, 2014

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.